4
Changes in Ownership
CORCEPT THERAPEUTICS INC Filed Acc 0000950170-23-068373
Chief Accounting Officer sold 5,000 shares at $26.00 ($130,000)
- Chief Accounting Officer acquired 5,000 shares (option exercise)
- Chief Accounting Officer acquired 920 shares (grant or award)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Lyon Joseph Douglas Chief Accounting Officer | 2023-12-01 | Option exercise 10b5-1 | +2,568 | $11.35 | $29,147 | 8,422 | D |
| Lyon Joseph Douglas Chief Accounting Officer | 2023-12-01 | Sale 10b5-1 | −2,568 | $26.00 | $66,768 | 5,854 | D |
| Lyon Joseph Douglas Chief Accounting Officer | 2023-12-04 | Option exercise 10b5-1 | +2,432 | $11.35 | $27,603 | 8,286 | D |
| Lyon Joseph Douglas Chief Accounting Officer | 2023-12-04 | Sale 10b5-1 | −2,432 | $26.00 | $63,232 | 5,854 | D |
| Lyon Joseph Douglas Chief Accounting Officer | 2023-12-01 | Grant or award 10b5-1 | +460 | $25.97 | $11,946 | 6,314 | D |
| Lyon Joseph Douglas Chief Accounting Officer | 2023-12-01 | Grant or award 10b5-1 | +460 | 6,774 | D | ||
| Derivatives | |||||||
| Lyon Joseph Douglas Chief Accounting Officer | 2023-12-01 | Option exercise · Stock option (right to buy) 10b5-1 | −5,000 | 44,167 | D | ||
| Open-market sales · 5,000 sh · avg $26.00 · $130,000 | |||||||
Loading xslF345X05/ownership.xml…